Zealand Phar­ma aims to raise $900M; Boehringer dis­con­tin­ues three Phase 2 tri­als

Plus, news about Lund­beck, Ot­su­ka, Ju­bi­lant Phar­ma, Fron­tier Med­i­cines, As­traZeneca and Benev­o­len­tAI:

Zealand Phar­ma tar­gets $900M raise: The Dan­ish biotech aims to se­cure the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER